Takeshi Terashima
Overview
Explore the profile of Takeshi Terashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
1326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanabe N, Saeki I, Yamaoka K, Kawaoka T, Tomonari T, Tani J, et al.
Anticancer Res
. 2025 Mar;
45(3):1117-1125.
PMID: 40037890
Background/aim: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the...
2.
Nishitani M, Okada H, Nio K, Hayashi T, Terashima T, Iida N, et al.
Int J Mol Sci
. 2025 Feb;
26(4).
PMID: 40003897
Mint3 enhances aerobic ATP production with subsequent nuclear translocation of hypoxia-inducible factor-1 (HIF-1) and activation of angiogenesis-related genes. It remains unclear if and when Mint3 is activated and whether it...
3.
Terashima T, Harada K, Yamashita T
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39936601
The concept and definition of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare condition accounting for only 1% of all primary liver cancers, has shifted in recent years. The latest World Health...
4.
Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, et al.
J Gastroenterol
. 2025 Jan;
60(3):368-369.
PMID: 39878838
No abstract available.
5.
Terashima T, Kido H, Takata N, Hayashi T, Seki A, Nakagawa H, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858059
: Atezolizumab and bevacizumab combination therapy has been established as a standard of care for first-line treatment; however, its efficacy and safety have not been fully evaluated for patients previously...
6.
Miyazawa M, Yanagi M, Chiba T, Nagai K, Kido H, Sugimoto S, et al.
Intern Med
. 2025 Jan;
PMID: 39814388
Whether or not pancreaticobiliary maljunction (PBM) is a risk factor for pancreatic cancer (PC) is unclear. We present a case of metachronous PC with PBM diagnosed after cholecystectomy for gallbladder...
7.
Terashima T, Nio K, Koshikawa N, Ueno M, Toyama T, Miyazawa M, et al.
BJC Rep
. 2025 Jan;
3(1):2.
PMID: 39809945
Background: The identification of effective diagnostic and prognostic biomarkers is critical to improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). We explored the potential of serum levels of...
8.
Fukushi K, Imaoka H, Ikeda M, Mizusawa J, Morizane C, Okusaka T, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39775866
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity...
9.
Okada M, Ohgino K, Horiuchi K, Sayama K, Arai D, Watase M, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768737
Atezolizumab, an immune checkpoint inhibitor (ICI), was used in a phase III clinical trial, i.e., the OAK trial, of previously treated patients with non-small cell lung cancer. We aimed to...
10.
Kimura M, Nishikawa T, Shimakami T, Terashima T, Horii R, Fukuda M, et al.
Glob Health Med
. 2025 Jan;
6(6):404-415.
PMID: 39741996
Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected...